📊 PHGE Key Takeaways
Is BiomX Inc. (PHGE) a Good Investment?
BiomX faces severe financial distress with negative stockholders' equity of -$1.3M, indicating technical insolvency, combined with persistent operating losses of -$41.5M and negative operating cash flow of -$26.4M. The company's liquidity position is critically strained with a current ratio of 0.87x and long-term debt of $11.2M exceeding total assets of $5.8M, presenting substantial going concern risks.
Why Buy BiomX Inc. Stock? PHGE Key Strengths
- Maintains $4.4M in cash and equivalents providing short-term runway
- Relatively low current liabilities of $751.1K reducing immediate payment obligations
- Minimal capital expenditure of $2.0K suggests operational discipline
PHGE Stock Risks: BiomX Inc. Investment Risks
- Negative stockholders' equity of -$1.3M indicates technical insolvency and balance sheet deterioration
- Operating cash flow burn rate of -$26.4M with no revenue (N/A) suggests unsustainable business model
- Long-term debt of $11.2M significantly exceeds total assets creating severe leverage and refinancing risk
- Current ratio of 0.87x signals acute liquidity stress and short-term solvency concerns
- Negative interest coverage of -48.8x indicates inability to service debt obligations
- Extreme negative ROA of -626% demonstrates value destruction
Key Metrics to Watch
- Cash burn rate and months of runway remaining at current operating cash flow
- Revenue recognition and business operations status
- Debt refinancing or covenant violation announcements
- Stockholders' equity trajectory toward recovery or further deterioration
- Insider buying/selling patterns and management confidence signals
BiomX Inc. (PHGE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PHGE Profit Margin, ROE & Profitability Analysis
PHGE vs Healthcare Sector: How BiomX Inc. Compares
How BiomX Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BiomX Inc. Stock Overvalued? PHGE Valuation Analysis 2026
Based on fundamental analysis, BiomX Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BiomX Inc. Balance Sheet: PHGE Debt, Cash & Liquidity
PHGE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BiomX Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $58.31 reflects profitable operations.
PHGE Revenue Growth, EPS Growth & YoY Performance
BiomX Inc. Dividends, Buybacks & Capital Allocation
PHGE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BiomX Inc. (CIK: 0001739174)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PHGE
What is the AI rating for PHGE?
BiomX Inc. (PHGE) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PHGE's key strengths?
Claude: Maintains $4.4M in cash and equivalents providing short-term runway. Relatively low current liabilities of $751.1K reducing immediate payment obligations.
What are the risks of investing in PHGE?
Claude: Negative stockholders' equity of -$1.3M indicates technical insolvency and balance sheet deterioration. Operating cash flow burn rate of -$26.4M with no revenue (N/A) suggests unsustainable business model.
What is PHGE's revenue and growth?
BiomX Inc. reported revenue of N/A.
Does PHGE pay dividends?
BiomX Inc. does not currently pay dividends.
Where can I find PHGE SEC filings?
Official SEC filings for BiomX Inc. (CIK: 0001739174) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PHGE's EPS?
BiomX Inc. has a diluted EPS of $22.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PHGE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BiomX Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PHGE stock overvalued or undervalued?
Valuation metrics for PHGE: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PHGE stock in 2026?
Our dual AI analysis gives BiomX Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PHGE's free cash flow?
BiomX Inc.'s operating cash flow is $-26.4M, with capital expenditures of $2.0K.
How does PHGE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.87 (avg: 2).